Heart valve infection trial questions need for common antibiotic
NCT ID NCT07253688
Summary
This study aims to find out if doctors can safely skip adding the antibiotic rifampin to standard treatment for serious staph infections on artificial heart valves. It will enroll 330 patients with these infections to compare outcomes between those who receive rifampin and those who do not. The goal is to see if avoiding this drug is just as effective and reduces potential side effects and drug interactions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS ENDOCARDITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
RECRUITINGMontreal, Quebec, H4A4S1, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.